- $1.33bn
- $953.14m
- $2.37m
- 35
- 10
- 53
- 23
Annual balance sheet for Upstream Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 17.1 | 110 | 470 |
| Net Total Accounts Receivable | |||
| Net Total Receivables | 0.502 | 0.359 | 1.24 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 18.3 | 117 | 479 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.164 | 0.202 | 2.37 |
| Other Long Term Assets | |||
| Total Assets | 18.5 | 117 | 482 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | 4.86 | 6.51 | 10.7 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 11.8 | 9.39 | 11.9 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Unrealized Gain / Loss | |||
| Total Equity | 6.67 | 108 | 470 |
| Total Liabilities & Shareholders' Equity | 18.5 | 117 | 482 |
| Total Common Shares Outstanding |